- Home
- MBRX vs BLRX Comparison
MBRX vs BLRX Comparison
Compare MBRX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- BLRX
- Stock Information
- Founded
- MBRX 2015
- BLRX 2003
- Country
- MBRX United States
- BLRX Israel
- Employees
- MBRX N/A
- BLRX N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- BLRX Health Care
- Exchange
- MBRX Nasdaq
- BLRX Nasdaq
- Market Cap
- MBRX 14.7M
- BLRX 12.1M
- IPO Year
- MBRX 2016
- BLRX 2011
- Fundamental
- Price
- MBRX $0.91
- BLRX $3.09
- Analyst Decision
- MBRX Strong Buy
- BLRX Buy
- Analyst Count
- MBRX 2
- BLRX 2
- Target Price
- MBRX $6.00
- BLRX $26.00
- AVG Volume (30 Days)
- MBRX 399.4K
- BLRX 15.5K
- Earning Date
- MBRX 05-13-2025
- BLRX 05-27-2025
- Dividend Yield
- MBRX N/A
- BLRX N/A
- EPS Growth
- MBRX N/A
- BLRX N/A
- EPS
- MBRX N/A
- BLRX N/A
- Revenue
- MBRX N/A
- BLRX $28,940,000.00
- Revenue This Year
- MBRX N/A
- BLRX N/A
- Revenue Next Year
- MBRX N/A
- BLRX N/A
- P/E Ratio
- MBRX N/A
- BLRX N/A
- Revenue Growth
- MBRX N/A
- BLRX 502.92
- 52 Week Low
- MBRX $0.40
- BLRX $2.30
- 52 Week High
- MBRX $5.29
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- MBRX 41.99
- BLRX 47.99
- Support Level
- MBRX $1.00
- BLRX $3.01
- Resistance Level
- MBRX $1.14
- BLRX $3.25
- Average True Range (ATR)
- MBRX 0.08
- BLRX 0.17
- MACD
- MBRX -0.00
- BLRX -0.01
- Stochastic Oscillator
- MBRX 10.00
- BLRX 17.10
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.